Ingrezza Miss Takes Neurocrine Biosciences (NBIX) PT Down To $110 At Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Neurocrine Bio. (NBIX) PT Lowered to $102 at H.C. Wainwright
December 13, 2018 11:09 AM ESTH.C. Wainwright analyst Andrew Fein lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $102.00 (from $162.00) while maintaining a Buy rating.
... MoreNeurocrine Bio. (NBIX) PT Lowered to $105 at Oppenheimer
December 13, 2018 9:30 AM ESTOppenheimer analyst Jay Olson lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $105.00 (from $140.00) while maintaining a Outperform rating.
Olson commented, "T-Force-GOLD missed the primary endpoint, sending NBIX shares down 14% on 12/12 (vs. NBI +1.3% and S&P 500 +0.5%) on the loss of this important... More



